High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1882-1890

  Gerard, Lauren M ^a,b   Imrie, Kevin R ^a,b   Mangel, Joy ^c   Buckstein, Rena ^a,b   Doherty, Mary ^a,d   MacKenzie, Robert ^a,d   Cheung, Matthew C ^a,b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

high dose methotrexate; Primary CNS lymphoma; whole brain radiotherapy

Indexed keywords

FOLINIC ACID; METHOTREXATE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; GAIT DISORDER; HUMAN; INCONTINENCE; LARGE CELL LYMPHOMA; MALE; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; PROCARBAZINE; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 80053219520     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.584004     Document Type: Article

References (40)

1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States,1985- 1999. Neuro Oncol 2006;8:27-37. (Pubitemid 43154448)
2. Haldorsen IS, Krossnes BK, Aarseth JH, et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003:time trends in a 15-year national survey. Cancer 2007;110:1804-1814.
3. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non- Hodgkin lymphoma. Cancer 2002;95:1504-1510.
4. Kadan-Lottick NS, Skluzarek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer 2002;95:193-202. (Pubitemid 34743498)
5. Mead GM, Bleehen NM, Gregor A, et al. A Medical Research Council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer 2000;89:1359-1370.
6. Ferreri AJM, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference onMalignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003;21:2407-2414. (Pubitemid 46621879)
7. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-195. (Pubitemid 24237996)
8. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-268. (Pubitemid 29488384)
9. DeAngelis L, Seiferheld W, Schold C, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Onoclogy Group Study 93-10. J Clin Oncol 2002;20:4643-4648. (Pubitemid 36025280)
10. Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr D, de Graaf SSN. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing. Cancer 2002;94:1815-1820.
11. Neuwelt EA, Guastadisegni PE, Varallyay P, Doolittle ND. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. Am J Neuroradiol 2005;26:258-265. (Pubitemid 43073302)
12. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-863. (Pubitemid 28108717)
13. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-1049. (Pubitemid 46594133)
14. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495. (Pubitemid 46594018)
15. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24: 4570-4574. (Pubitemid 46630953)
16. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results. Neurology 1996;46:1757-1759. (Pubitemid 26185811)
17. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000-3006. (Pubitemid 28417419)
18. Cheng AL, Yeh KH, Uen WC, Hung RL, Liu MY, Wang CH. Systemic chemotherapy alone for patients with nonacquired immunodeficiency syndrome-related central nervous system lymphoma: a pilot of the BOMES protocol. Cancer 1998;82:1946-1951.
19. Khan RB, Weije S, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? . J Neurooncol 2002;58:175-178. (Pubitemid 34784848)
20. Macdonald DR, Cascino TL, Schold SC, Cairncross JC. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280. (Pubitemid 20195640)
21. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-5043. (Pubitemid 46224010)
22. DeAngelis LM, Yaholm J. Primary central nervous system lymphoma.In: DeVita V, editor. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp 2330-2332.
23. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994;81:188-195. (Pubitemid 24237996)
24. Tetef ML, Margolin KA, Doroshow JH, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 2000;46:19-26. (Pubitemid 30432170)
25. Boiardi A, Silvani A, Valentini S, Salmaggi A, Allegranza A, Broggi G. Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. J Neurol 1993;241:96-100. (Pubitemid 23362657)
26. Blay JY,CouhourD,CarrieC, et al.TheC5Rprotocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995;86 2922-2929.
27. Bessell EM, Graus F, Punt JA, Firth J. Primary non- Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996;14:945-954. (Pubitemid 26085541)
28. Glass J, Shusik C, Hochberg FH, Cher L, Gruber M. Therapy of primary central nervous system lymphoma with preirradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996;30:257-265. (Pubitemid 26377550)
29. Dent S, Eapen L, Girard A, Hugenholtz H, DaSilva V, Stewart D. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J Neurooncol 1996;28:25-30. (Pubitemid 26128679)
30. Korfel A, Thiel E. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leuk Lymphoma 1998;30:609-617. (Pubitemid 28393695)
31. Brada M, Hjiyiannakis D, Hines F, Tralsh D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998;40:1157-1162. (Pubitemid 28152932)
32. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomized phase 2 trial. Lancet 2009;374:1512-1520.
33. Herrlinger U, Schabet M, Brugger W, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51:247-252. (Pubitemid 34111448)
34. Herrlinger U, Kuker Wk, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous sys tem lymphoma: final report. Ann Neurol 2005;57:843-847. (Pubitemid 40798622)
35. Ferreri A, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21: 266-272. (Pubitemid 46606155)
36. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5715. (Pubitemid 46631313)
37. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomized, noninferiority trial. Lancet Oncol 2010;11:1036-1047.
38. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144-3150.
39. Gavrillovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Neurooncol 2006;58:175-178.
40. Shah G, Yahalom J, Correa DD, Lai RK, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-4735. (Pubitemid 350086474)